Inhibition of angiogenesis by peptide analogs of high molecular weight kininogen domain 5
AssigneesTemple University of the Commonwealth System of Higher Education, Du Pont Pharmaceuticals Company
InventorsRobert W. Colman, Shaker A. Mousa
Life of this patent
Estimating the term…
Abstract
Peptide analogs of the high molecular weight kininogen domain 5 are potent inhibitors of angiogenesis. The peptides have the formula X1-(HGLGHGHEQQHGKGH)-X2 (I) wherein X1 is from zero to 25 amino acids; X2 is from zero to 60 amino acids. Methods of inhibiting endothelial cell proliferation and angiogenesis are provided.
Claims25
A method of inhibiting endothelial cell proliferation comprising contacting endothelial cells with a compound of the formula
- X1-(SEQ ID NO:2)-X2 (I)
- wherein
- X1 is from zero to 25 amino acids;
- and
- X2 is from zero to 60 amino acids,
- and wherein said compound optionally comprises an amino-terminal and optionally comprises a carboxy-terminal protecting group.
A method of inhibiting endothelial cell proliferation comprising contacting endothelial cells with the compound SEQ ID NO:8, wherein said compound optionally comprises an amino-terminal and optionally comprising a carboxy-terminal protecting group.
A method of inhibiting endothelial cell proliferation comprising contacting endothelial cells with the compound SEQ ID NO:11, wherein said compound optionally comprises an amino-terminal and optionally comprising a carboxy-terminal protecting group.
A method of inhibiting endothelial cell proliferation comprising contacting endothelial cells with the compound SEQ ID NO:12, wherein said compound optionally comprises an amino-terminal and optionally comprising a carboxy-terminal protecting group.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula
- X1-(SEQ ID NO:2)-X2 (I)
- wherein
- X1 is from zero to 25 amino acids;
- and
- X2 is from zero to 45 amino acids,
- and wherein said compound optionally comprises an amino-terminal and optionally comprises a carboxy-terminal protecting group.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound SEQ ID NO:8, wherein said compound optionally comprises an amino-terminal and optionally comprises a carboxy-terminal protecting group.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound SEQ ID NO:11, wherein said compound optionally comprises an amino-terminal and optionally comprises a carboxy-terminal protecting group.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound SEQ ID NO:12, wherein said compound optionally comprises an amino-terminal and optionally comprises a carboxy-terminal protecting group.
Dependencies are inferred from the claim text.